University Clinical Hospital of Valencia
Welcome,         Profile    Billing    Logout  
 2 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vercet, Carlos Solano
ARES, NCT04769895 / 2021-001841-11: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Active, not recruiting
3
66
Europe
MaaT013
MaaT Pharma, MaaT Pharma
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
11/24
11/25
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
NCT03225417 / 2016-002503-26: Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

Active, not recruiting
1/2
142
Europe
Ixazomib, X16082, Tacrolimus, Prograf, Sirolimus, Rapamune, Any prophylaxis for GVHD, Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any in vitro or in vivo.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Spanish Clinical Research Network - SCReN
Hematopoietic Stem Cell Transplantation, Multiple Myeloma
01/24
12/24
CARTemis-1, NCT05982275: Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

Not yet recruiting
1/2
25
Europe
CARTemis-1
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Multiple Myeloma, Allogeneic Stem Cell Transplantation
12/29
12/29
Bruixola, Gema
UPSTREAM, NCT03088059 / 2017-000086-74: Biomarker-based Study in R/M SCCHN

Checkmark Data from UPSTREAM trial in combination with monalizumab for SCCHN
Oct 2019 - Oct 2019: Data from UPSTREAM trial in combination with monalizumab for SCCHN
Active, not recruiting
2
340
Europe
Afatinib, Palbociclib, standard of care, IPH2201, Monalizumab, Durvalumab, Niraparib, INCAGN01876
European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
06/25
12/25
FIDALGO, JOSE ALEJANDRO PEREZ
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
FLASH, NCT04733183 / 2018-004104-19: Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Active, not recruiting
2
98
Europe
Dacarbazine, DTIC, onfekafusp alfa, L19TNF
Philogen S.p.A., Philogen S.p.A.,
Soft Tissue Sarcoma
12/25
12/25
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
Uplift, NCT03319628 / 2020-000630-17: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruiting
1/2
523
US
upifitamab rilsodotin, XMT-1536, UpRi
Mersana Therapeutics
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
05/23
10/24
Borrero, Alicia
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28

Download Options